Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Ono Pharma |
---|---|
Information provided by: | Ono Pharma |
ClinicalTrials.gov Identifier: | NCT00311038 |
The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for multi-slice CT.
Condition | Intervention | Phase |
---|---|---|
Coronary Artery Disease |
Drug: ONO-1101 |
Phase II |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Pilot Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT) Due to Suspected Coronary Artery Disease |
Ages Eligible for Study: | 20 Years to 74 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Japan | |
Kanto Region Facility | |
Kanto, Japan | |
Hokuriku Region Facility | |
Hokuriku, Japan | |
Kyusyu Region Facility | |
Kyusyu, Japan |
Study Director: | Project Leaders Development Planning | Ono Pharma |
Study ID Numbers: | ONO-1101-24 |
Study First Received: | April 3, 2006 |
Last Updated: | September 10, 2007 |
ClinicalTrials.gov Identifier: | NCT00311038 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
ONO-1101 Landiolol Hydrochloride Multi-slice CT Coronary Artery Disease |
Arterial Occlusive Diseases Neurotransmitter Agents Heart Diseases Adrenergic Agents Myocardial Ischemia Vascular Diseases Cardiovascular Agents Ischemia |
Arteriosclerosis Landiolol Coronary Disease Adrenergic beta-Antagonists Adrenergic Antagonists Anti-Arrhythmia Agents Coronary Artery Disease |
Arterial Occlusive Diseases Neurotransmitter Agents Heart Diseases Molecular Mechanisms of Pharmacological Action Adrenergic Agents Myocardial Ischemia Physiological Effects of Drugs Vascular Diseases Cardiovascular Agents Arteriosclerosis |
Landiolol Pharmacologic Actions Coronary Disease Therapeutic Uses Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists Anti-Arrhythmia Agents Coronary Artery Disease |